Skip to main content

Table 4 Summary of structural sensitivity analysis

From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

Parameter Min ICER Max ICER Output differences
Treatment effect: HF only endpoints €7,903 €9,196 €1,293
CV: mortality Kaplan Meier vs Gompertz €9,196 €10,313 €1,117
Ivabradine treatment duration: 5 years vs lifelong €8,145 €9,196 €1,051
NYHA extrapolation: LoCF vs Assumption based €9,099 €9,669 €569
QoL weights: Exclude age adjustment vs include age adjustment €9,099 €9,353 €254
CV mortality: Weibull vs Gompertz €8,946 €9,196 €250
QoL weights: SHIFT predicted vs external literature €8,859 €9,099 €240
NYHA extrapolation: LoCF vs SHIFT predicted €8,966 €9,099 €133
CV mortality: exponential vs gompertz €9,070 €9,196 €126
Titration visit and ECG costs excluded vs included €9,077 €9,099 €22
  1. CV: cardiovascular; QoL: Quality of Life; ICER: incremental cost effectiveness ratio; HF: Heart Failure; ECG: electrocardiographic changes; NYHA: New York Heart Association; LoCF: Last observation carried forward.